Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Damien Giacchero
Based on 11 articles published since 2010
(Why 11 articles?)
||||

Between 2010 and 2020, D. Giacchero wrote the following 11 articles about Melanoma.
 
+ Citations + Abstracts
1 Clinical Trial Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit. 2017

Montaudié, Henri / Cerezo, Michael / Bahadoran, Philippe / Roger, Coralie / Passeron, Thierry / Machet, Laurent / Arnault, Jean-Philippe / Verneuil, Laurence / Maubec, Eve / Aubin, François / Granel, Florence / Giacchero, Damien / Hofman, Véronique / Lacour, Jean-Philippe / Maryline, Allegra / Ballotti, Robert / Rocchi, Stéphane. ·Department of Dermatology, University Hospital of Nice, Nice, France. · Team 12, Centre Méditerranéen de Médecine Moléculaire, INSERM, U1065, Nice, France. · Team 1, Centre Méditerranéen de Médecine Moléculaire, INSERM, U1065, Nice, France. · Department of Dermatology, Clinical Research Center, Archet Hospital, Nice, France. · Department of Clinical Research and Innovation, University Hospital of Nice, Nice, France. · Department of Dermatology, CHRU de Tours, University Francois Rabelais of Tours, Tours, France. · Department of Dermatology, University Hospital of Amiens, Amiens, France. · Department of Dermatology, University Hospital of Caen, Caen, France. · Department of Dermatology, University Hospital of Paris, Hospital Bichat, Nice, France. · Department of Dermatology, University Hospital of Besançon, Besançon, France. · Department of Dermatology, University Hospital of Nancy, Nancy, France. · Department of Oncology, Antoine Lacassagne Cancer Center, University of Nice-Sophia, Nice, France. · Laboratory of Clinical and Experimental Pathology and Human Biobank, Nice University Hospital, Nice, France. · Faculty of Medicine, INSERM 1081 Team 3 IRCAN, University of Nice Sophia Antipolis, Nice, France. ·Pigment Cell Melanoma Res · Pubmed #28122176.

ABSTRACT: -- No abstract --

2 Article [Stage III melanoma: Sentinel node biopsy, completion lymph node dissection and prospects of adjuvant therapy. A French national survey on current and envisaged practices]. 2020

Orion, C / Dinulescu, M / Dalac-Rat, S / Giacchero, D / Jouary, T / Lebbé, C / Leccia, M-T / Maubec, E / Meyer, N / Mortier, L / Dupuy, A / Anonymous3831048. ·Service de dermatologie, CHU de Rennes, 2, rue Henri-le-Guilloux, 35000 Rennes, France. · Service de dermatologie, CHRU François-Mitterrand, 14, rue Gaffarel, BP 77908, 21079 Dijon cedex, France. · Cabinet de dermatologie, 11, rue Châteauneuf, 06000 Nice, France. · Service de dermatologie, CH de Pau, 4, boulevard Hauterive, 64000 Pau, France. · Service d'oncodermatologie, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France. · Service de dermatologie, CHU Grenoble Alpes, boulevard de la Chantourne, 38700 La Tronche, France. · Service de dermatologie, hôpital Avicenne, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France. · Dermatologie, IUC et CHU de Toulouse, 24, chemin de Pouvourville, 31059 Toulouse, France. · Service de dermatologie, CHRU de Lille, 2, avenue Oscar-Lambret, 59037 Lille, France. · Service de dermatologie, CHU de Rennes, 2, rue Henri-le-Guilloux, 35000 Rennes, France. Electronic address: alain.dupuy@chu-rennes.fr. · Service de dermatologie, CHU de Rennes, 2, rue Henri-le-Guilloux, 35000 Rennes, France; Service de dermatologie, CHRU François-Mitterrand, 14, rue Gaffarel, BP 77908, 21079 Dijon cedex, France; Cabinet de dermatologie, 11, rue Châteauneuf, 06000 Nice, France; Service de dermatologie, CH de Pau, 4, boulevard Hauterive, 64000 Pau, France; Service d'oncodermatologie, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; Service de dermatologie, CHU Grenoble Alpes, boulevard de la Chantourne, 38700 La Tronche, France; Service de dermatologie, hôpital Avicenne, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France; Dermatologie, IUC et CHU de Toulouse, 24, chemin de Pouvourville, 31059 Toulouse, France; Service de dermatologie, CHRU de Lille, 2, avenue Oscar-Lambret, 59037 Lille, France. ·Ann Dermatol Venereol · Pubmed #31761496.

ABSTRACT: BACKGROUND: The recent publication of randomized trials investigating the efficacy of adjuvant therapy and completion lymph node dissection at microscopic stage III melanoma calls for a reappraisal of melanoma management from different angles: indications for sentinel lymph node biopsy, indications for completion lymph node dissection in microscopic-stage disease, and adjuvant therapies. Our objective was to evaluate current practices and to question French onco-dermatologists about any changes they envisaged in their practices in the light of recent publications. METHODS: We conducted a national survey among members of the Cutaneous Oncology Group of the French Society of Dermatology in October 2017. RESULTS: Forty French health centers were included, and 53 individual responses were collected. Sentinel lymph node biopsy for melanoma was performed at 75 % of the centers. Before the summer of 2017 and the publication of MSLT-II (proving the absence of any therapeutic benefits for complete lymph node dissection in microscopic stage III melanoma), when a positive sentinel lymph node was diagnosed, immediate completion lymph node dissection was performed at 90 % of the centers. After the publication of MSLT-II, 45 % of the respondents considered stopping this practice. The risk-benefit ratio prompted prescription of nivolumab and of combined dabrafenib+trametinib as adjuvant therapy by respectively 96 % and 79 % of respondents, while the corresponding rates for interferon and ipilimumab were only 21 % and 15 %. CONCLUSION: Early melanoma management stands on the verge of major changes thanks to the arrival of efficient adjuvant therapies and a decrease in immediate completion lymph node dissections for patients with microscopic stage III is also anticipated.

3 Article Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis. 2015

Tichet, Mélanie / Prod'Homme, Virginie / Fenouille, Nina / Ambrosetti, Damien / Mallavialle, Aude / Cerezo, Michael / Ohanna, Mickaël / Audebert, Stéphane / Rocchi, Stéphane / Giacchero, Damien / Boukari, Fériel / Allegra, Maryline / Chambard, Jean-Claude / Lacour, Jean-Philippe / Michiels, Jean-François / Borg, Jean-Paul / Deckert, Marcel / Tartare-Deckert, Sophie. ·1] INSERM, U1065, Microenvironnement, Signalisation et Cancer, Centre Méditerranéen de Médecine Moléculaire (C3M), 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France [2] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France. · 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] Centre Hospitalier Universitaire (CHU) de Nice, Hôpital Pasteur, Laboratoire Central d'Anatomo Pathologie, 06002 Nice, France. · 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] INSERM, U1065, Biologie et Pathologies des Mélanocytes, C3M, 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France. · CRCM, INSERM U1068, Institut Paoli-Calmettes, Aix-Marseille Université, UM105; CNRS UMR7258, BP 30059, 13273 Marseille, France. · 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] CHU de Nice, Hôpital Archet 2, Service de Dermatologie, 06202 Nice, France. · 1] INSERM, U1065, Microenvironnement, Signalisation et Cancer, Centre Méditerranéen de Médecine Moléculaire (C3M), 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France [2] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [3] CHU de Nice, Hôpital Archet 2, Service de Dermatologie, 06202 Nice, France. · 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] INSERM, U1091, CNRS, UMR 7277, iBV, Faculté des Sciences, Parc Valrose, 06108 Nice, France. ·Nat Commun · Pubmed #25925867.

ABSTRACT: Disruption of the endothelial barrier by tumour-derived secreted factors is a critical step in cancer cell extravasation and metastasis. Here, by comparative proteomic analysis of melanoma secretomes, we identify the matricellular protein SPARC as a novel tumour-derived vascular permeability factor. SPARC deficiency abrogates tumour-initiated permeability of lung capillaries and prevents extravasation, whereas SPARC overexpression enhances vascular leakiness, extravasation and lung metastasis. SPARC-induced paracellular permeability is dependent on the endothelial VCAM1 receptor and p38 MAPK signalling. Blocking VCAM1 impedes melanoma-induced endothelial permeability and extravasation. The clinical relevance of our findings is highlighted by high levels of SPARC detected in tumour from human pulmonary melanoma lesions. Our study establishes tumour-produced SPARC and VCAM1 as regulators of cancer extravasation, revealing a novel targetable interaction for prevention of metastasis.

4 Article Regulation of NADPH-dependent Nitric Oxide and reactive oxygen species signalling in endothelial and melanoma cells by a photoactive NADPH analogue. 2014

Rouaud, Florian / Romero-Perez, Miguel / Wang, Huan / Lobysheva, Irina / Ramassamy, Booma / Henry, Etienne / Tauc, Patrick / Giacchero, Damien / Boucher, Jean-Luc / Deprez, Eric / Rocchi, Stéphane / Slama-Schwok, Anny. ·INSERM U1065 team 1, Université de Nice Sophia Antipolis et Centre Méditerranéen de Médecine Moléculaire, Nice, France. · Pole of Pharmacology and Therapeutics, FATH5349, IREC, UCL Medical Sector, Brussels, Belgium. · Laboratoire de Biologie et Pharmacologie Appliquée (LBPA), ENS-Cachan, CNRS UMR 8113, IDA FR3242, Cachan, France. · CNRS UMR 8601, Université Paris Descartes, 45 rue des Saints Pères, Paris, France. · Service de Dermatologie, Hôpital Archet II, CHU Nice, France;. · Virologie et Immunologie Moléculaires, UR 892, INRA, Jouy en Josas, France. ·Oncotarget · Pubmed #25296975.

ABSTRACT: Nitric Oxide (NO) and Reactive oxygen species (ROS) are endogenous regulators of angiogenesis-related events as endothelial cell proliferation and survival, but NO/ROS defect or unbalance contribute to cancers. We recently designed a novel photoactive inhibitor of NO-Synthases (NOS) called NS1, which binds their NADPH site in vitro. Here, we show that NS1 inhibited NO formed in aortic rings. NS1-induced NO decrease led to an inhibition of angiogenesis in a model of VEGF-induced endothelial tubes formation. Beside this effect, NS1 reduced ROS levels in endothelial and melanoma A375 cells and in aorta. In metastatic melanoma cells, NS1 first induced a strong decrease of VEGF and blocked melanoma cell cycle at G2/M. NS1 decreased NOX(4) and ROS levels that could lead to a specific proliferation arrest and cell death. In contrast, NS1 did not perturb melanocytes growth. Altogether, NS1 revealed a possible cross-talk between eNOS- and NOX(4) -associated pathways in melanoma cells via VEGF, Erk and Akt modulation by NS1 that could be targeted to stop proliferation. NS1 thus constitutes a promising tool that modulates NO and redox stresses by targeting and directly inhibiting eNOS and, at least indirectly, NADPH oxidase(s), with great potential to control angiogenesis.

5 Article Macular eruption revealing hypomelanotic cutaneous melanoma metastases: diagnostic role of dermoscopy. 2014

Hammami-Ghorbel, Houda / Giacchero, Damien / Hofman, Véronique / Poissonnet, Gilles / Passeron, Thierry / Lacour, Jean Philippe / Bahadoran, Philippe. ·Department of Dermatology, University Hospital of Nice, Nice, France. · CHU Nice, Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France. · Department of Head and Neck Surgery, Cancer Center Antoine-Lacassagne, University Nice Sophia-Antipolis, Nice, France. · Department of Dermatology, University Hospital of Nice, Nice, France; INSERM U 1065, Team 1, University Hospital of Nice, Nice, France; Clinical Research Centre, University Hospital of Nice, Nice, France. Electronic address: bahadoran.p@chu-nice.fr. ·J Am Acad Dermatol · Pubmed #24355285.

ABSTRACT: -- No abstract --

6 Article Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. 2013

Ohanna, Mickaël / Cheli, Yann / Bonet, Caroline / Bonazzi, Vanessa F / Allegra, Marylin / Giuliano, Sandy / Bille, Karine / Bahadoran, Philippe / Giacchero, Damien / Lacour, Jean Philippe / Boyle, Glen M / Hayward, Nicholas F / Bertolotto, Corine / Ballotti, Robert. ·Inserm U1065, Centre Méditerranéen de Médecine Moléculaire, Equipe 1, Biologie et pathologies des mélanocytes: de la pigmentation cutanée au mélanome. Equipe labellisée Ligue 2013, Nice, F-06204, France. ·Oncotarget · Pubmed #24344100.

ABSTRACT: Here, we showed that the secretome of senescent melanoma cells drives basal melanoma cells towards a mesenchymal phenotype, with characteristic of stems illustrated by increased level of the prototype genes FN1, SNAIL, OCT4 and NANOG. This molecular reprogramming leads to an increase in the low-MITF and slow-growing cell population endowed with melanoma-initiating cell features. The secretome of senescent melanoma cells induces a panel of 52 genes, involved in cell movement and cell/cell interaction, among which AXL and ALDH1A3 have been implicated in melanoma development. We found that the secretome of senescent melanoma cells activates the STAT3 pathway and STAT3 inhibition prevents secretome effects, including the acquisition of tumorigenic properties. Collectively, the findings provide insights into how the secretome of melanoma cells entering senescence upon chemotherapy treatments increases the tumorigenicity of naïve melanoma cells by inducing, through STAT3 activation, a melanoma-initiating cell phenotype that could favor chemotherapy resistance and relapse.

7 Article Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. 2013

Cerezo, Michaël / Tichet, Mélanie / Abbe, Patricia / Ohanna, Mickaël / Lehraiki, Abdelali / Rouaud, Florian / Allegra, Maryline / Giacchero, Damien / Bahadoran, Philippe / Bertolotto, Corine / Tartare-Deckert, Sophie / Ballotti, Robert / Rocchi, Stéphane. ·Equipe Biologie et Pathologie des cellulesmelanocytaire: de la pigmentation cutanee au melanome, Centre Mediterraneen de Medecine Moleculaire (C3M), INSERM, U1065. ·Mol Cancer Ther · Pubmed #23741061.

ABSTRACT: Metformin was reported to inhibit the proliferation of many cancer cells, including melanoma cells. In this report, we investigated the effect of metformin on melanoma invasion and metastasis development. Using different in vitro approaches, we found that metformin inhibits cell invasion without affecting cell migration and independently of antiproliferation action. This inhibition is correlated with modulation of expression of proteins involved in epithelial-mesenchymal transition such as Slug, Snail, SPARC, fibronectin, and N-cadherin and with inhibition of MMP-2 and MMP-9 activation. Furthermore, our data indicate that this process is dependent on activation of AMPK and tumor suppressor protein p53. Finally, we showed that metformin inhibits melanoma metastasis development in mice using extravasation and metastasis models. The presented data reinforce the fact that metformin might be a good candidate for clinical trial in melanoma treatment.

8 Article Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. 2013

Bahadoran, Philippe / Allegra, Maryline / Le Duff, Florence / Long-Mira, Elodie / Hofman, Paul / Giacchero, Damien / Passeron, Thierry / Lacour, Jean-Philippe / Ballotti, Robert. ·Department of Dermatology, Archet Hospital-Centre Hospitalier Universitaire de Nice, Nice cedex 03, France. ·J Clin Oncol · Pubmed #23715574.

ABSTRACT: -- No abstract --

9 Minor A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib. 2014

Allegra, Maryline / Giacchero, Damien / Segalen, Coralie / Dumaz, Nicolas / Butori, Catherine / Hofman, Véronique / Hofman, Paul / Lacour, Jean-Philippe / Bertolotto, Corine / Bahadoran, Philippe / Ballotti, Robert. ·Equipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; Department of Dermatology, CHU Nice, Nice, France. · Department of Dermatology, CHU Nice, Nice, France. · Equipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France. · INSERM U976, Université Paris Diderot, Sorbonne Paris Cité, Paris, France. · IRCAN Equipe 3, and Hospital-Integrated Tumor Biobank, INSERM U 1081, Nice, France. · UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France; IRCAN Equipe 3, and Hospital-Integrated Tumor Biobank, INSERM U 1081, Nice, France. · Department of Dermatology, CHU Nice, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France. · Equipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France. · Equipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; Department of Dermatology, CHU Nice, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France; Clinical Research Centre, CHU Nice, Nice, France. Electronic address: bahadoran.p@chu-nice.fr. · Equipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; Department of Dermatology, CHU Nice, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France. Electronic address: ballotti@unice.fr. ·J Invest Dermatol · Pubmed #24317392.

ABSTRACT: -- No abstract --

10 Minor Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients. 2013

Hofman, Véronique / Ilie, Marius / Long-Mira, Elodie / Giacchero, Damien / Butori, Catherine / Dadone, Bérengère / Selva, Eric / Tanga, Virginie / Passeron, Thierry / Poissonnet, Gilles / Emile, Jean-François / Lacour, Jean-Philippe / Bahadoran, Philippe / Hofman, Paul. · ·J Invest Dermatol · Pubmed #23303445.

ABSTRACT: -- No abstract --

11 Minor Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy? 2011

Passeron, Thierry / Lacour, Jean-Philippe / Allegra, Maryline / Ségalen, Coralie / Deville, Anne / Thyss, Antoine / Giacchero, Damien / Ortonne, Jean-Paul / Bertolotto, Corine / Ballotti, Robert / Bahadoran, Philippe. · ·Exp Dermatol · Pubmed #22092579.

ABSTRACT: Selection for targeted therapies in melanoma is currently based on the search for mutations in selected genes. We aimed at evaluating the interest of signalling and chemosensitivity studies in addition to genotyping for assessing the best suitable treatment in an individual patient. We extracted genomic DNA and melanoma cells from tumor tissue of a skin metastasis of a 17-year-old woman with stage IV melanoma progressing despite three successive lines of treatment. Despite the absence of mutation in BRAF, NRAS cKIT, the MAPK pathway was activated and a significant response to sorafenib, a mitogen-activated protein kinase (MAPK)/RAF inhibitor, was found in signalling and chemosensitivity assays. A treatment combining sorafenib and dacarbazine produced a partial response for 9 months, with marked necrosis in some lesions. Chemosensitivity assays and signalling pathway studies could be of great value in addition to genotyping for assessing the most appropriate treatment in melanoma.